Get the Stockscreener App
16.95
17.87%
2.57
Pre-market:
17.10
0.15
+0.88%
Biohaven Ltd stock is traded at $16.95, with a volume of 15.74M.
It is up +17.87% in the last 24 hours and up +18.37% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
See More
Previous Close:
$14.38
Open:
$14.24
24h Volume:
15.74M
Relative Volume:
5.59
Market Cap:
$2.56B
Revenue:
-
Net Income/Loss:
$-647.68M
P/E Ratio:
-2.9894
EPS:
-5.67
Net Cash Flow:
$-594.49M
1W Performance:
+19.87%
1M Performance:
+18.37%
6M Performance:
+52.02%
1Y Performance:
+7.76%
1-Day Range:
$13.00
$18.24
1-Week Range:
$13.00
$18.24
52-Week Range:
$7.48
$18.57
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
16.95 | 2.04B | 0 | -647.68M | -594.49M | -5.67 |
VRTX
Vertex Pharmaceuticals Inc
|
547.29 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
814.79 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,047.10 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
149.66 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
215.44 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Canaccord Genuity | Buy |
| Feb-06-26 | Initiated | Goldman | Buy |
| Jan-21-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-26-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Nov-05-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Initiated | Citigroup | Buy |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
Why Biohaven (BHVN) Is Down 9.1% After Reporting Narrower Q2 and H1 Net Losses - simplywall.st
HC Wainwright Decreases Earnings Estimates for Biohaven - MarketBeat
NewEdge Wealth LLC Invests $3.66 Million in Biohaven Ltd. $BHVN - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Biohaven (BHVN) Pulls Back 1.4% as Shares Approach Key $13.91 Support ZoneChannel Breakout - vinanet.vn
Biohaven Ltd. $BHVN Shares Bought by Quantinno Capital Management LP - MarketBeat
Is Biohaven’s Narrowing Losses and AI Board Hire Altering The Investment Case For Biohaven (BHVN)? - Sahm
Biohaven (BHVN) Could Be 73% Undervalued As Regeneron Deal Expands - simplywall.st
Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline? - Yahoo Finance
Woodline Partners (BHVN) discloses 5.1% beneficial stake in Biohaven - Stock Titan
Renaissance Technologies LLC Acquires New Position in Biohaven Ltd. $BHVN - MarketBeat
Biohaven (BHVN) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Bank of America Securities Reaffirms Their Buy Rating on Biohaven Ltd. (BHVN) - The Globe and Mail
Biohaven 2Q Loss/Shr 91c >BHVN - Moomoo
Biohaven Ltd. (BHVN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Biohaven Pharma stock price target raised to $23 by RBC Capital - Investing.com Nigeria
Biohaven Supported by Multiple Pipeline Catalysts, Cash Runway Into 2027, RBC Says - Moomoo
Biohaven Ltd. (BHVN) Stock Analysis: Exploring The 57.73% Potential Upside For Investors - DirectorsTalk Interviews
Biohaven (BHVN) Holds Near Key Support After Modest PullbackPre-Earnings Momentum - vinanet.vn
Biohaven Ltd. (BHVN) stock price, news, quote and history - Yahoo Finance Australia
Biohaven (NYSE:BHVN) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
Biohaven narrows Q2 losses 29%, initiates pivotal Graves' trial - scanx.trade
Biohaven Ltd. Announces Q2 2026 Financial Results Highlighting Reduced Losses and R&D Spending - Kalkine Media
Biohaven reports Q2 2026 net loss of $137.3M, cash and marketable securities $267.9M - TradingView
Biohaven (NYSE: BHVN) reports $267.8M H1 2026 loss and $267.9M in liquidity - Stock Titan
Biohaven Ltd. reports results for the quarter ended June 30Earnings Summary - TradingView
Biohaven Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Biohaven Ltd. $BHVN Shares Purchased by The Manufacturers Life Insurance Company - MarketBeat
Biohaven earnings set to show cash burn ahead of epilepsy data - Investing.com UK
Understanding Momentum Shifts in (BHVN) - Stock Traders Daily
Biohaven Ltd. (BHVN) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Biohaven Ltd (BHVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Biohaven (BHVN) Institutional Ownership 2026 - MarketBeat
Biohaven (BHVN) Adds AI Expertise To Its Board, Is The Valuation Gap Too Wide? - simplywall.st
Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors - Morningstar
Biohaven Adds Technology Investor John Yetimoglu to Board as AI Strategy Advances - citybiz
Biohaven Ltd. Announces Appointment of John Yetimoglu to Board of Directors, Effective August 6, 2026 - marketscreener.com
Press Release: Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors - Moomoo
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 71.53% Potential Upside in the Biotech Sector - directorstalkinterviews.com
Biohaven (BHVN) Expected to Release Quarterly Earnings on Monday - MarketBeat
Biohaven Ltd. $BHVN Shares Bought by Janus Henderson Group PLC - MarketBeat
Stempoint Capital LP Takes $13.49 Million Position in Biohaven Ltd. $BHVN - MarketBeat
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 58% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
How Biohaven’s (BHVN) Trade Secret Verdict Shapes Its Intellectual Property Defense Strategy - simplywall.st
Federal jury awards Yale University, Biohaven $4M in trade secret suit - Westfair Communications
Yale, Biohaven Win $4M In Biotech Trade Secret Trial - Law360
Why is Biohaven Pharmaceutical stock gaining today? By Investing.com - Investing.com Canada
Yale, Biohaven Win $4 Million Verdict Over Drug-Development Tech - Bloomberg Law News
Federal jury awards Yale, Biohaven $4M in lawsuit over trade secrets - Hartford Business Journal
Biohaven and Yale win $4M verdict in trade secret case - Investing.com Nigeria
Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million - TradingView
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):